The sitagliptin drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Sitagliptin drug is used for the treatment of type 2 diabetes. It is a white non-hygroscopic powder somewhat crystalline in nature. Insulin is a type of hormone which is produced naturally in the body. Production of insulin takes place in the pancreas. Insulin is responsible to control the blood sugar level in the body. Diabetes is a condition in which the body does not produce enough insulin. In some cases, the body does not make use of the insulin which is produced in it. People with diabetes need to regularly meet the need for insulin which is necessary for the body. As per health experts, the maintenance of diet is considered important in maintaining diabetes. Drugs like sitagliptin are prescribed with a proper diet to enhance the level of insulin in the body. A substance known as glucagon enhances the production of sugar in the liver. Sitagliptin reduces the amount of glucagon which is produced by the pancreas. This in turn reduces the level of glucose in human blood. As diabetes is a chronic disease, people can develop other diseases such as cardiovascular disease, stroke, kidney disease, etc. cardiovascular disease can lead to life-threatening conditions if not taken care of.
A full report of Global Sitagliptin Drug Market is available at:https://orionmarketreports.com/global-sitagliptin-drug-market/72034/
Januvia is a drug that has sitagliptin as an active ingredient and is prescribed in the treatment of type 2 diabetes. Sometimes, this drug is prescribed with other medications as a combination for more effectiveness. It belongs to a class of drugs known as Antidiabetics, Dipeptidyl Peptidase-IV. Janumet is another drug that has sitagliptin as the active ingredient and is prescribed for type 2 diabetes. This drug has a combination of sitagliptin and metformin. Insulin level which is produced after major meals in the body is regulated by sitagliptin. The glucose level in the body is reduced by metform in which regulates the absorption of glucose by the intestines. As per International Diabetes Federation, around 541 million adults globally are at risk of developing type 2 diabetes in 2021. The total count of people with diabetes is going to rise to 643 million by the year 2030. In the year 2021, a total of $966 billion was spent on diabetes in the health sector.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Disease
- By End-User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Glenmark Pharmaceutical Ltd., Merck & Co., Inc, Sun Pharmaceutical Industries Ltd.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Sitagliptin Drug Market Report by Segment
By Disease
- Type 2 Diabetes
- Others
By End-User
- Hospital
- Clinic
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
